enGene Inc.

enGene Inc.

October 25, 2007 08:00 ET

enGene, Inc. to present Key Data at Two Diabetes Conferences

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 25, 2007) - enGene, Inc., a privately held biotechnology company developing an innovative approach for the long-term treatment of diabetes called GEMS™-Insulin, announced today that two scientific co-founders will be presenting new data on the company's core technology:

- Dr. Anthony T. Cheung, Chief Scientific Officer will present at 8:50AM during the 7th Annual Diabetes Technology Meeting on October 27, 2007, at the Hyatt Regency San Francisco Airport Hotel during the "Insulin and Metabolic Peptide Delivery" Session. Dr. Cheung will present data on insulin replacement gene therapy for Type 1 diabetes using enGene's novel, integrative, non-viral vector.

enGene's studies demonstrated that mice continue to produce human insulin in a regulated, meal-dependent fashion for more than 130 days after a single administration of the GEMS™-Insulin therapy. The abstract of these data was selected as the highest rated out of over 190 abstracts submitted, resulting in an invitation to present during the formal meeting session.

- Dr. Timothy Kieffer, VP of Research at enGene and Professor, Dept. of Cellular and Physiological Sciences and Surgery at the University of British Columbia, is presenting at the Annual Meeting of the Canadian Diabetes Association on Saturday, October 27, 2007 at 2:00PM during the session entitled "New Insights into Type 1 diabetes pathogenesis and therapy" at the Vancouver Convention and Exhibition Centre.

Dr. Kieffer's talk, entitled "Gene therapy approaches for generating surrogate beta cells in Type 1 diabetes", will highlight results from recent studies showing that intestinal K-cells, when genetically transformed into insulin-producing cells, do not undergo the autoimmune destruction that occurs in pancreatic beta cells in Type 1 diabetes. This important finding further supports the use of these cells as surrogates for meal-regulated insulin production and release in patients with insulin-dependant diabetes.

More about enGene, Inc. and GEMS™ for Diabetes

enGene's technology, Gut Endocrine-cell Modification System (GEMS™), utilizes the protein synthesizing capacity of normal, healthy cells existing in a small, targeted area of the duodenum to secrete a therapeutic protein, following delivery of a gene construct in a non-viral vector. This treatment is designed to enable the patients' own cells to produce insulin in a regulated, meal-dependent fashion resulting in the physiological control of blood glucose levels.

Other potential applications for GEMS™ include obesity, anaemia, haemophilia and several gastrointestinal disorders.

Additional information about the Company, as well as scientific information related to the above presentation, is available at www.engeneinc.com.

Contact Information

  • enGene Inc.
    Eric A. Adams
    CEO
    (604) 221-4362 x230
    (604) 221-4369 (FAX)
    Website: www.engeneinc.com